SLC18A2 and Familial prostate cancer: The group found that SLC18A2 mRNA expression levels were significantly decreased in prostate cancer samples, with low expression levels significantly associated with PSA recurrence after radical prostatectomy (multivariate hazard ratio (HR) 0.13, p < 0.05) suggestive of independent prognostic value [56].